Onat, AltanAltay, ServetYuksel, MuratKaradeniz, YusufCan, GunayYuksel, HusniyeAdemoglu, Evin2024-06-122024-06-1220172149-22632149-2271https://doi.org/10.14744/AnatolJCardiol.2016.7024https://hdl.handle.net/20.500.14551/18076Objective: We investigated the possible association of serum acylation stimulating protein (ASP) with cardiometabolic disorders and the evidence of autoimmune activation. Methods: Population-based randomly selected 1024 participants were cross-sectionally and prospectively analyzed. ASP concentrations were measured with a validated ELISA kit. Correlations were sought separately in subjects with no cardiometabolic disorders (n=427) designated as healthy. Results: ASP was positively correlated with total testosterone and inversely correlated with platelet activating factor (PAF), PAF-acetylhydrolase (AH), in each gender, and positively correlated in healthy men with lipoprotein [Lp](a) and apolipoprotein B. Correlations of ASP with PAF values =22 nmol/L were abolished, contrasted to a strongly inverse one in subjects with PAF Conclusion: Findings can be explained by the notion of operation of immune responses against both ASP and oxidized PAF-like lipids of Lp(a) to yield for reduced values and increased likelihood of cardiometabolic disorders.en10.14744/AnatolJCardiol.2016.7024info:eu-repo/semantics/openAccessAcylation Stimulating ProteinAutoimmunityType-2 DiabetesLipoprotein(A)Metabolic SyndromePlatelet Activating FactorPhospholipidsMetabolic SyndromePhospholipase A(2)Complement C3DiseaseLipidsDefinitionHumansWomenRiskArticle17297106Q4WOS:0003969014000052-s2.0-8501530934127599666Q3